Stockscreener 앱 받기
2.71
6.27%
0.16
전일 마감가:
$2.55
열려 있는:
$3
하루 거래량:
1,805
Relative Volume:
0.13
시가총액:
$33.50M
수익:
-
순이익/손실:
$-11.73M
주가수익비율:
-1.9601
EPS:
-1.3826
순현금흐름:
$-10.37M
1주 성능:
-4.91%
1개월 성능:
+7.97%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$2.67
$3.00
1주일 범위
$2.52
$3.00
52주 변동 폭
$1.80
$3.23
Medicus Pharma Ltd Stock (MDCX) Company Profile
MDCX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
2.67 | 33.50M | 0 | -11.73M | -10.37M | -1.3826 |
|
VRTX
Vertex Pharmaceuticals Inc
|
487.85 | 125.43B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
707.46 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
666.65 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.62 | 35.33B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.90 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Medicus Pharma Ltd 주식(MDCX)의 최신 뉴스
Quantum Biopharma in Court With Dr. Raza Bokhari on January 24 - WICZ
Merck KGaA (OTCMKTS:MKKGY) and Medicus Pharma (NASDAQ:MDCX) Critical Contrast - Defense World
Medicus Pharma Ltd. Announces Change of Auditor - TipRanks
Medicus Pharma (NASDAQ:MDCX) Upgraded at Brookline Capital Management - Defense World
Brookline starts coverage on Medicus Pharma stock with Buy rating - Investing.com India
Brookline starts coverage on Medicus Pharma stock with Buy rating By Investing.com - Investing.com Nigeria
Medicus Pharma initiated at buy by Brookline Capital - MSN
Cartoning Machines Market Size to Approach USD 13.58 Bn by 2034 - GlobeNewswire Inc.
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases - Proactive Investors USA
Medicus Pharma CEO charts course for 2025 with clinical milestones for SkinJect - Proactive Investors Australia
Medicus Pharma achieves FDA MUMS approval for equine squamous cell carcinoma patchICYMI - Proactive financial news
Medicus Pharma achieves key milestone with FDA MUMS designation for cancer treatment in Horses - Proactive financial news
Medicus Pharma’s horse skin cancer treatment wins MUMS designation from FDA - Proactive Investors Australia
Medicus Pharma Eyes Veterinary Market with FDA Designation - TipRanks
Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch - The Manila Times
Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation - GlobeNewswire
Medicus Pharma Secures FDA MUMS Status for Novel Cancer Treatment Patch in $200M+ Equine Market - StockTitan
Medicus Pharma Ltd. Announces Minor Use Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch - Marketscreener.com
Medicus Pharma CEO on basal-cell carcinoma trial progress – ICYMI - Proactive Investors Australia
ITF Therapeutics Appoints Erica L. Monaco, CPA, as Chief Operating Officer - citybiz
ITF Therapeutics LLC Announces Appointment of Erica L. Monaco, CPA, as Chief Operating Officer - BioSpace
Medicus Pharma and Swanielle partner to expand BCC drug trial to Asia-Pacific - Yahoo Finance
Medicus Pharma collaborates to expand mid-stage cancer treatment study in Asia-Pacific region - MSN
Medicus Pharma Share PriceMDCX, RNS News, Articles, Quotes, & Charts (CVE:MDCX) - Proactive Investors Australia
Medicus Pharma eyes pivotal trial for skin cancer therapy as Phase 2 enrollment progresses - Proactive Investors Australia
Medicus Pharma’s Phase 2 study enrolls 25% of patients and expands into Asia-Pacific Region - Proactive Investors UK
Medicus Pharma partners with Swanielle to expand skin cancer study into Asia-Pacific - Proactive Investors Australia
Medicus Pharma Expands Asia-Pacific Clinical Study - TipRanks
Medicus Pharma enters collaboration agreement with Swanielle - TipRanks
Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region - GlobeNewswire
Medicus Pharma Expands BCC Treatment Trial to Asia-Pacific After Promising Phase 1 Results - StockTitan
MDCX: Medicus Pharma 3Q 2024 Financial Results Reported; Stock Now Trades Both in Canada and on Nasdaq After Completing an IPO in the U.S. - Zacks Small Cap Research
V.MDCX: Medicus Pharma Has Begun Trading on Nasdaq under the ticker MDCX after Completing an IPO in the U.S. The SKNJCT-003 Phase 2 clinical trial continues. - MSN
Medicus Pharma Ltd. Expands with Strategic Takeover - TipRanks
Medicus Pharma prices IPO at $4.125 per unit - MSN
Medicus Pharma unveils ex-GSK and Pfizer senior as chief medical officer - Proactive Investors Australia
Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer - GlobeNewswire
Leadership Changes at Medicus Pharma Ltd - TipRanks
MDCXMedicus Pharma Ltd. Latest Stock News & Market Updates - StockTitan
Medicus Pharma makes debut on Nasdaq raising $4M to advance skin cancer trialICYMI - Proactive Investors Australia
Medicus Pharma Closes $4M IPO, Trades on Nasdaq - TipRanks
Medicus Pharma Completes $4M IPO for Skin Cancer Treatment Development | MDCX Stock News - StockTitan
Medicus Pharma completes IPO, becomes second local life sciences company to go public in 2024 - The Business Journals
Medicus Pharma CEO Dr Raza Bokhari on $4M Nasdaq IPO & Phase 2 trial - Proactive Investors UK
Canada Market's biggest losers: Medicus Pharma Ltd. -40.99%, Bragg Gaming Group Inc. -24.43% at midday - Business Upturn
Canada Market's top losers: Pangenomic Health Inc. down 78.67%, Medicus Pharma Ltd down 42.99% - Business Upturn
Medicus Pharma announces pricing of US IPO - Proactive Investors Australia
Medicus Pharma prices IPO at $4.125 per unit (TSXV:MDCX:CA) - Seeking Alpha
Medicus Pharma Ltd (MDCX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.43%
3.18%
자본화:
|
볼륨(24시간):